 | Up a level |
Meier, FM; Frommer, KW; Dinser, R; Walker, UA; Czirjak, L; Denton, CP; Allanore, Y; Distler, O; Riemekasten, G; Valentini, G; Müller-Ladner, U; Matucci-Cerinic, M; Guiducci, S; Tyndall, A; Lapadula, G; Iannone, F; Becvar, R; Sierakowsky, S; Kowal-Bielecka, O; Cutolo, M; ... (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the rheumatic diseases, 71(8), pp. 1355-1360. London: BMJ Publishing Group 10.1136/annrheumdis-2011-200742
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
Haefeli, M; Elfering, A; Aebi, M; Freeman, BJ; Fritzell, P; Guimaraes Consciencia, J; Lamartina, C; Mayer, M; Lund, T; Boos, N (2008). What comprises a good outcome in spinal surgery? A preliminary survey among spine surgeons of the SSE and European spine patients. European spine journal, 17(2008), pp. 104-116. Berlin: Springer 10.1007/s00586-007-0541-5
D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2007). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of oncology, 19(4), pp. 739-745. Oxford: Oxford University Press 10.1093/annonc/mdm564
